Can a diabetes drug protect kidneys without making you lose weight?
Weight Loss-Independent Mechanisms of Kidney Protection with Glucagon-Like Peptide-1 Receptor Agonists and Implications for Clinical Practice
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looks at whether a popular diabetes and weight-loss drug helps kidneys work better, even if the patient doesn't lose weight.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 51 / 5
Evidence Score
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looks at whether a popular diabetes and weight-loss drug helps kidneys work better, even if the patient doesn't lose weight.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 51 / 5
Evidence Score
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Publication
Related Content
Claims (2)
In patients with type 2 diabetes and chronic kidney disease, the medication semaglutide is associated with a lower chance of developing kidney failure and other kidney-related complications, even when accounting for changes in body weight.
Glucagon-like peptide-1 receptor agonists may improve kidney function through mechanisms that do not primarily depend on reducing body weight, according to summaries of human clinical trials.